Skip to main content

Advertisement

SpringerLink
Log in

Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nurses

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Epidemiologic studies indicate on an increased risk of cardiovascular disease and cancer in shift workers, although the underling mechanism is obscure. Heparanase directly enhances tissue factor (TF) activity leading to increased factor Xa production and subsequent activation of the coagulation system. In the present study, a comparison of coagulation markers among healthy shift working (SW) vs. healthy daytime working (DW) female nurses was performed. Thirty SW and 30 DW female nurses were enrolled. For each of the 60 participants, blood was drawn between 7:00 and 8:00 a.m. and at least 8 h after the last work shift. Plasma was studied for coagulation marker that included TF/heparanase procoagulant activity, TF activity, heparanase procoagulant activity, heparanase level, factor Xa level, plasminogen activator inhibitor 1 (PAI-1), plasminogen, α2-antiplasmin, fibrinogen, global protein C, von Willebrand factor, and D-dimer by chromogenic assays and enzyme-linked immunosorbent assays (ELISAs). Sleep quality was assessed by self-report according to the Pittsburgh Sleep Quality Index. The heparanase procoagulant activity increased by 2-fold and the TF/heparanase procoagulant activity increased by 1.5-fold in SW nurses compared to DW nurses (P < 0.05). Factor Xa levels and PAI-1 levels were significantly higher among SW nurses compared to the DW group (22 vs. 18 ng/ml, P < 0.05, and 32 vs. 22 ng/ml, P < 0.005, respectively). No significant differences were found in the other tested coagulation markers between the study groups. Heparanase procoagulant activity, factor Xa level, and PAI-1 level were significantly higher in SW nurses compared to the DW group. These alterations of blood coagulation activation may potentially contribute to cardiovascular and cancer morbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wang XS, Armstrong ME, Cairns BJ, Key TJ, Travis RC (2011) Shift work and chronic disease: the epidemiological evidence. Occup Med (Lond) 61:78–89

    Article  Google Scholar 

  2. Vyas MV, Garg AX, Iansavichus AV, Costella J, Donner A, Laugsand LE et al (2012) Shift work and vascular events: systematic review and meta-analysis. BMJ 345:e4800

    Article  PubMed Central  PubMed  Google Scholar 

  3. Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME (2014) Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin 64:207–218

    Article  PubMed Central  PubMed  Google Scholar 

  4. Mazzoccoli G, Vinciguerra M, Papa G, Piepoli A (2014) Circadian clock circuitry in colorectal cancer. World J Gastroenterol 20:4197–4207

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Knutsson A, Alfredsson L, Karlsson B, Akerstedt T, Fransson EI, Westerholm P et al (2013) Breast cancer among shift workers: results of the WOLF longitudinal cohort study. Scand J Work Environ Health 39:170–177

    Article  PubMed  Google Scholar 

  6. Varki A (2007) Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 110:1723–1729

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124:58S–68S

    Article  CAS  PubMed  Google Scholar 

  8. Oishi K, Ohkura N (2013) Chronic circadian clock disruption induces expression of the cardiovascular risk factor plasminogen activator inhibitor-1 in mice. Blood Coagul Fibrinolysis 24:106–108

    Article  CAS  PubMed  Google Scholar 

  9. Meade TW, Chakrabarti R, North WR (1977) Associations between fibrinolytic activity and other variables in an industrial population. Adv Exp Med Biol 82:219–221

    CAS  PubMed  Google Scholar 

  10. Freeman C, Parish CR (1998) Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 330(Pt 3):1341–1350

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Pikas DS, Li JP, Vlodavsky I, Lindahl U (1998) Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 273:18770–18777

    Article  CAS  PubMed  Google Scholar 

  12. Parish CR, Freeman C, Hulett MD (2001) Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471:M99–M108

    CAS  PubMed  Google Scholar 

  13. Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108:341–347

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Nadir Y, Brenner B, Zetser A, Ilan N, Shafat I, Zcharia E et al (2006) Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 4:2443–2451

    Article  CAS  PubMed  Google Scholar 

  15. Nadir Y, Brenner B, Gingis-Velitski S, Levy-Adam F, Ilan N, Zcharia E et al (2008) Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost 99:133–141

    CAS  PubMed  Google Scholar 

  16. Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I (2010) Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 95:1927–1934

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Nadir Y, Kenig Y, Drugan A, Shafat I, Brenner B (2011) An assay to evaluate heparanase procoagulant activity. Thromb Res 128:e3–e8

    Article  CAS  PubMed  Google Scholar 

  18. Peled E, Rovitsky A, Axelman E, Norman D, Brenner B, Nadir Y (2012) Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin. Thromb Res 130:129–134

    Article  CAS  PubMed  Google Scholar 

  19. Matan M, Axelman E, Brenner B, Nadir Y (2013) Heparanase procoagulant activity is elevated in women using oral contraceptives. Hum Reprod 28:2372–2380

    Article  CAS  PubMed  Google Scholar 

  20. Nadir Y, Sarig G, Axelman E, Meir A, Wollner M, Shafat I et al (2014) Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients. Thromb Res 134:639–642

    Article  CAS  PubMed  Google Scholar 

  21. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S et al (2004) Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117:2249–2258

    Article  CAS  PubMed  Google Scholar 

  22. Shafat I, Zcharia E, Nisman B, Nadir Y, Nakhoul F, Vlodavsky I et al (2006) An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 341:958–963

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Andreotti F, Kluft C (1991) Circadian variation of fibrinolytic activity in blood. Chronobiol Int 8:336–351

    Article  CAS  PubMed  Google Scholar 

  24. Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF et al (2000) CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem 275:36847–36851

    Article  CAS  PubMed  Google Scholar 

  25. Mutch NJ, Wilson HM, Booth NA (2001) Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 60:341–347

    Article  CAS  PubMed  Google Scholar 

  26. Eren M, Painter CA, Gleaves LA, Schoenhard JA, Atkinson JB, Brown NJ et al (2003) Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice. J Thromb Haemost 1:2389–2396

    Article  CAS  PubMed  Google Scholar 

  27. Skurk T, Hauner H (2004) Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 28:1357–1364

    Article  CAS  PubMed  Google Scholar 

  28. Mertens I, Van der Planken M, Corthouts B, Wauters M, Peiffer F, De Leeuw I et al (2001) Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 33:602–607

    Article  CAS  PubMed  Google Scholar 

  29. Esterson YB, Kishore P, Koppaka S, Li W, Zhang K, Tonelli J et al (2012) Fatty acid-induced production of plasminogen activator inhibitor-1 by adipose macrophages is greater in middle-aged versus younger adult participants. J Gerontol A Biol Sci Med Sci 67:1321–1328

    Article  PubMed Central  PubMed  Google Scholar 

  30. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213

    Article  CAS  PubMed  Google Scholar 

  31. Shochat T, Tzischinsky O, Oksenberg A, Peled R (2007) Validation of the Pittsburgh Sleep Quality Index Hebrew translation (PSQI-H) in a sleep clinic sample. Isr Med Assoc J 9:853–856

    PubMed  Google Scholar 

  32. Strike PC, Magid K, Whitehead DL, Brydon L, Bhattacharyya MR, Steptoe A (2006) Pathophysiological processes underlying emotional triggering of acute cardiac events. Proc Natl Acad Sci U S A 103:4322–4327

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Jiang Q, Gingles NA, Olivier MA, Miles LA, Parmer RJ (2011) The anti-fibrinolytic SERPIN, plasminogen activator inhibitor 1 (PAI-1), is targeted to and released from catecholamine storage vesicles. Blood 117:7155–7163

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Thrombosis and Hemostasis Unit, Rambam Health Care Campus, Haifa, Israel

    Yona Nadir, Gleb Saharov, Ron Hoffman, Anat Keren-Politansky, Inna Tzoran & Benjamin Brenner

  2. Department of Nursing, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel

    Gleb Saharov & Tamar Shochat

Authors
  1. Yona Nadir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gleb Saharov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ron Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anat Keren-Politansky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Inna Tzoran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Benjamin Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tamar Shochat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yona Nadir.

Additional information

Informed consent was obtained from all the patients for being included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nadir, Y., Saharov, G., Hoffman, R. et al. Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nurses. Ann Hematol 94, 1213–1219 (2015). https://doi.org/10.1007/s00277-015-2345-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2345-8

Keywords

Search

Navigation